Technology | November 23, 2009

New Ultrasound Thrombolysis System Introduced for DVT


November 23, 2009 – Using less lytic drug and offering faster clot dissolution than traditional deep vein thrombosis (DVT) treatments, EKOS Corp. launched the EkoSonic MACH4e at the recent VEITH Symposium in New York.

The MACH4e upgrade achieves faster removal of arterial and venous clots, which the company says accelerates thrombolysis by up to 40 percent (1). For simplicity, the new system automates a number of manual steps, making it easier to use.

The company said the system can be used to treat clots in veins, arteries, IVC filters and difficult-to-reach places such as behind valves. The ultrasound waves help increase drug uptake by the clot and uses 50-70 percent less lytic drug (3). The device reduces the risk pf thrombus fracture or breakage (4), reducing the risk of distal embolism, or post thrombotic syndrome (PTS).

During the Veith Symposium Mark J. Garcia, M.D., program director, vascular and interventional radiology fellowship and section chief, vascular and interventional radiology at Christiana Care Health Services in Newark, Del., presented a series of 35 patients with chronic, hard and occlusive DVT that were successfully treated with endovascular techniques. He said the EKOs system is a major breakthrough in restoring quality of life to the patient.

“The EKOS ultrasound assisted thrombolysis, in addition to standard angioplasty and stenting techniques, led to successful venous recanalization and patency with improved venous outflow,” said Dr. Garcia. “Our results suggest that the ability to successfully recanalize chronically occluded venous segments in patients with PTS, benefit the patient by reducing their symptoms and allowing them to enjoy an improved quality of life.”

EKOS pioneered the development and clinical application of ultrasonic accelerated drug delivery in medicine, introducing its first system for the treatment of vascular thrombosis in 2005. In 2008, the company introduced its second-generation EkoSonic Endovascular System with Rapid Pulse Modulation. In November 2009 introduced the MACH4e upgrade.

For more information: www.ekoscorp.com

References:)
1. EKOS in vitro data on file
2. Francis, CW, eta al. “Ultrasound Accelerates Transport of Recombinant tissue Plasminogen Activator into Clots.” Phys Med Biol, 2008.
3. Parikh, S., et al. “Ultrasound-Accelerated Thrombolysis for the Treatment of Deep Vein Thrombosis: Initial Clinical Experience.” Journal of Vascular and Interventional Radiology, April 2008, 19, pages 521-528.
4. Braatan, J., et al. “Ultrasound Reversibly Disaggregates Fibrin Fibers.” Thromb Haemost 78 (1997), pages 1063-8.


Related Content

News | Cardiovascular Clinical Studies

April 24, 2024 —Hello Heart, a digital leader in preventive heart health, today announced results from its latest study ...

Home April 24, 2024
Home
News | Cardiovascular Clinical Studies

April 22, 2024 — Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, welcomes the ...

Home April 22, 2024
Home
News | Cardiovascular Clinical Studies

April 16, 2024 — CVRx, Inc., a commercial-stage medical device company, announced today the availability of additional ...

Home April 16, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — Transcatheter aortic valve replacement (TAVR) was found to bring no increased risks and was associated ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — People with a buildup of fatty atherosclerotic plaque in the heart’s arteries considered at risk of ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Patients who took an angiotensin-converting enzyme (ACE) inhibitor while undergoing cancer treatment ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — One of the first studies to attempt to treat early-stage heart failure in patients with Type 2 diabetes ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — The investigational drug ninerafaxstat showed a good tolerability and safety profile, along with ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Administering tranexamic acid (TxA), a drug used to reduce bleeding during heart surgery, topically ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Using a web application to qualify individuals for treatment with a nonprescription statin closely ...

Home April 09, 2024
Home
Subscribe Now